Israel Roundup: War has little impact on venture capital investment; Web 2.0 investments make their debut; Google set to hire dozens of local engineers; high-tech wages on the rise; record Copaxone sales for Teva.
|
Israeli stem cell startup plans to use fund for expanding pipeline and marketing.
|
Generics companies scramble as Merck’s cholesterol-lowering statin loses its patent.
|
Bristol-Myers Squibb and Sanofi-Aventis reach agreement with Apotex on infringement claims.
|
All-cash deal will build generics powerhouse and third-biggest U.S. specialty drug firm.
|
A panel for the regulatory agency considers whether to recommend the multiple sclerosis drug return to the market.
|
Israeli drug giant to help finance and commercialize technology based on technology for targeting apoptotic cells.
|
The British drug company sues Teva over its plans to make a generic hyperactivity drug.
|
Indian pharma company outbids its rival Ranbaxy and others in a $570-million deal.
|
Israeli pharma firm bets big on India center and scouts for clinical research partners.
|
The two drug makers settle a patent dispute over a sleep drug, sending Cephalon’s shares up 5 percent.
|
Israel’s Teva is one step closer to becoming the No. 1 generic drug maker after Europe clears its $7.4B bid for U.S.-based IVAX.
|
Israeli drug maker granted six months to make a generic version of Pravachol.
|
The Swiss pharmaceutical company’s strong third-quarter earnings lift its stock.
|
As the Swiss giant aims for more power in the vaccine market, Chiron’s shares jump more than 18 percent.
|
Attorney General Lockyer takes 39 pharmaceutical companies to court for cheating the state’s Medi-Cal program.
|
Teva has a slow Q2 but looks to make it to the top ten pharma companies by the end of the decade.
|
Teva Pharmaceutical acquiring generic pharmaceutical maker IVAX, rendering Teva the largest generic drug maker.
|
Sales of Teva’s leading multiple sclerosis drug hit a record $291 million in the second quarter.
|
A U.S. judge upholds Eli Lilly’s Zyprexa patent, lifting company shares and zapping generic companies.
|